Use este identificador para citar ou linkar para este item:
https://repositorio.ufba.br/handle/ri/13435
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Poynard, Thierry | - |
dc.contributor.author | Bruix, Jordi | - |
dc.contributor.author | Schiff, Eugene R. | - |
dc.contributor.author | Diago, Moises | - |
dc.contributor.author | Berg, Thomas | - |
dc.contributor.author | Moreno Otero, Ricardo | - |
dc.contributor.author | Lyra, André Castro | - |
dc.contributor.author | Carrilho, Flair | - |
dc.contributor.author | Griffel, Louis H. | - |
dc.contributor.author | Boparai, Navdeep | - |
dc.contributor.author | Jiang, Ruiyun | - |
dc.contributor.author | Burroughs, Margaret | - |
dc.contributor.author | Brass, Clifford A. | - |
dc.contributor.author | Albrecht, Janice K. | - |
dc.creator | Poynard, Thierry | - |
dc.creator | Bruix, Jordi | - |
dc.creator | Schiff, Eugene R. | - |
dc.creator | Diago, Moises | - |
dc.creator | Berg, Thomas | - |
dc.creator | Moreno Otero, Ricardo | - |
dc.creator | Lyra, André Castro | - |
dc.creator | Carrilho, Flair | - |
dc.creator | Griffel, Louis H. | - |
dc.creator | Boparai, Navdeep | - |
dc.creator | Jiang, Ruiyun | - |
dc.creator | Burroughs, Margaret | - |
dc.creator | Brass, Clifford A. | - |
dc.creator | Albrecht, Janice K. | - |
dc.date.accessioned | 2013-10-31T18:12:57Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | http://repositorio.ufba.br/ri/handle/ri/13435 | - |
dc.description | Texto completo. Acesso restrito. p. 452–459 | pt_BR |
dc.description.abstract | Background & Aims: Therapeutic options for patients failing hepatitis C retreatment are limited. EPIC3 included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNa-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment. Methods: Patients with F2/F3 MFS who failed retreatment were randomized to PegIFNa-2b (0.5 lg/kg/week, n = 270) or observation (n = 270) for 36 months. Blinded liver biopsies obtained before retreatment and after maintenance therapy were evaluated using MFS and activity scores, and confirmatory testing was performed using FibroTest and ActiTest. Results: In total, 348 patients had paired biopsies: 192 patients had missing post-treatment biopsies and were considered as having no change in fibrosis/activity scores. In total, 16% of patients receiving PegIFNa-2b and 11% of observation patients had improvement in MFS (p = 0.32). More PegIFNa-2b than observation patients had improvement in activity score (20% vs. 9%; p <0.001). Among patients treated for >2.5 years, improvement in MFS or activity score was more common with PegIFNa-2b than observation (21% vs. 14%, p = 0.08 and 26% vs. 10%, p <0.001). FibroTest and ActiTest evaluations indicated significant benefit associated with PegIFNa-2b in terms of reduced fibrosis progression and improved activity score. The safety profile of PegIFNa-2b was similar to previous studies. Conclusions: PegIFNa-2b did not significantly improve MFS estimated by biopsy compared with observation; however, activity scores were significantly improved and MFS trended toward increased improvement with treatment durations >2.5 years. Both FibroTest and ActiTest were significantly improved during maintenance therapy | pt_BR |
dc.language.iso | en | pt_BR |
dc.publisher | Journal of Hepatology | pt_BR |
dc.rights | Acesso Aberto | pt_BR |
dc.source | http://dx.doi.org/10.1016/j.jhep.2012.11.001 | pt_BR |
dc.subject | Fibrosis | pt_BR |
dc.subject | Biomarkers | pt_BR |
dc.subject | Hepatitis C | pt_BR |
dc.subject | Liver | pt_BR |
dc.subject | FibroTest | pt_BR |
dc.title | Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study | pt_BR |
dc.title.alternative | Journal of Hepatology | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.description.localpub | Salvador | pt_BR |
dc.identifier.number | v. 58, n. 3 | pt_BR |
dc.embargo.liftdate | 10000-01-01 | - |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
8888888888888888.pdf | 958,82 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.